Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Policy / Regulatory

NMPA Releases 2025 Priority Approval Directory for Eight High-End Medical Device Categories

Fineline Cube Dec 29, 2025
Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Fineline Cube Dec 29, 2025
Company Drug

BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL

Fineline Cube Dec 29, 2025
Company Drug

GSK Launches Cabotegravir Injection in China for HIV Pre-Exposure Prophylaxis

Fineline Cube Jan 10, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) has announced the official commercial launch of its cabotegravir injection...

Company Deals

Insilico Medicine Raises USD 100 Million in Financing Round Led by Pudong and Hong Kong

Fineline Cube Jan 10, 2025

China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has reportedly raised USD 100 million in...

Company Deals

Haier Biomedical Terminates Acquisition Plan for Shanghai RAAS

Fineline Cube Jan 9, 2025

Haier Biomedical (SHA: 688139) has announced the termination of its plan to acquire Shanghai RAAS...

Company Drug

NHSA Revises 2024 NRDL Drug Information Based on Public Feedback

Fineline Cube Jan 9, 2025

China’s National Healthcare Security Administration (NHSA) has announced revisions to the information about certain drugs...

Company

Eli Lilly China’s Neuroscience VP Jiang Yifei Departs for New Opportunities

Fineline Cube Jan 9, 2025

Jiang Yifei, the current vice president of Eli Lilly (NYSE: LLY) China’s neuroscience division, has...

Company Deals

Fourier Intelligence Secures USD 109 Million in Series E Funding for Robotics Innovation

Fineline Cube Jan 9, 2025

China-based Shanghai Fourier Intelligence Co., Ltd, a leading developer of exoskeleton robotic products for rehabilitation...

Company Drug

Astellas’ Padcev and Keytruda Combo Cleared by NMPA for Urothelial Cancer

Fineline Cube Jan 9, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503) has announced marketing clearance by China’s National Medical Products...

Company Drug

HuidaGene Therapeutics Receives EMA Orphan Designation for HG004 Gene Therapy

Fineline Cube Jan 9, 2025

Shanghai-based genome medicines specialist HuidaGene Therapeutics has announced a positive opinion from the European Medicines...

Company Deals

China Medical System Licenses Alpha Cognition’s Zunveyl for Dementia Treatment in Asia

Fineline Cube Jan 9, 2025

China Medical System Holdings (CMS; HKG: 0867) has announced a license agreement with Alpha Cognition...

Company Deals

Huahai Pharmaceutical to Transfer Rights to Innovative Antidepressant HHT001 via Public Listing

Fineline Cube Jan 9, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) is set to transfer the patent and...

Company Drug

Mabwell’s 9MW2821 Granted Breakthrough Therapy Designation by CDE for Urothelial Carcinoma

Fineline Cube Jan 9, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that the Center for Drug...

Company Drug

Kelun Pharmaceutical’s Generic Mulpleta Gains NMPA Approval in China

Fineline Cube Jan 9, 2025

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that it has received marketing...

Company Deals

Alloy Therapeutics and Sanofi Collaborate on CNS Drug Development with AntiClastic Antisense Platform

Fineline Cube Jan 9, 2025

US-based Alloy Therapeutics Inc. has announced a target-specific collaboration and license agreement with Sanofi (NASDAQ:...

Company Drug

Fujian Cosunter’s COVID-19 Therapy GST-HG171/ritonavir Approved in Macau

Fineline Cube Jan 9, 2025

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that its Category 1 product,...

Company Medical Device

Medtronic’s Harmony TPV System Gains CE Mark for Minimally Invasive Heart Valve Treatment

Fineline Cube Jan 9, 2025

US-Irish firm Medtronic (NYSE: MDT) has announced that its Harmony Transcatheter Pulmonary Valve (TPV) System...

Company Deals

Biocytogen and Acepodia Partner to Develop Dual-Payload Bispecific ADCs for Oncology

Fineline Cube Jan 9, 2025

China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with Acepodia,...

Company Drug

Sanofi’s Sarclisa Gains NMPA Approval for Multiple Myeloma Treatment in China

Fineline Cube Jan 9, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from...

Company Deals

Araris Biotech and Chugai Pharmaceutical Collaborate on Novel ADC Development

Fineline Cube Jan 9, 2025

Switzerland-based oncology biotech Araris Biotech AG has announced a research collaboration and option to license...

Company Deals Drug

Mirror Biologics and Merck KGaA Collaborate on Phase II Trial for Colorectal Cancer Immunotherapy

Fineline Cube Jan 9, 2025

US-based Mirror Biologics, Inc., an off-the-shelf immunotherapy developer, has announced a clinical trial collaboration and...

Company Drug

Johnson & Johnson’s Posdinemab Receives FDA Fast Track Designation for Alzheimer’s Disease

Fineline Cube Jan 9, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) has announced that it has received Fast...

Posts pagination

1 … 167 168 169 … 602

Recent updates

  • Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio
  • Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal
  • Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing
  • Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China
  • BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.